Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
NASDAQ: SHPH · Real-Time Price · USD
0.3660
-0.0490 (-11.81%)
At close: Apr 11, 2025, 4:00 PM
0.3513
-0.0147 (-4.02%)
After-hours: Apr 11, 2025, 7:59 PM EDT
Company Description
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers.
The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system.
It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway.
The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Shuttle Pharmaceuticals Holdings, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Aug 31, 2022 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Anatoly Dritschilo |
Contact Details
Address: 401 Professional Drive, Suite 260 Gaithersburg, Maryland 20879 United States | |
| Phone | 240 403 4212 |
| Website | shuttlepharma.com |
Stock Details
| Ticker Symbol | SHPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.13 |
| CIK Code | 0001757499 |
| CUSIP Number | 825693203 |
| ISIN Number | US8256932034 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher Robert Cooper BBA, M.B.A., MBA | Interim Co-Chief Executive Officer |
| Peter Dale Dritschilo M.B.A., M.D. | President and Chief Operating Officer |
| Dr. Mira Jung Ph.D. | Co-Founder and Chief Scientific Officer for Biology |
| Dr. Tyvin A. Rich M.D. | Chief Clinical Officer and Chief Medical Officer |
| Dr. Milton Brown CSC, M.D., Ph.D. | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2025 | PRER14A | Filing |
| Apr 10, 2025 | 8-K | Current Report |
| Apr 4, 2025 | 8-K | Current Report |
| Mar 31, 2025 | ARS | Filing |
| Mar 31, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 19, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 424B3 | Prospectus |